These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9531264)

  • 1. Distinct peptide loading pathways for MHC class II molecules associated with alternative Ii chain isoforms.
    Bikoff EK; Kenty G; Van Kaer L
    J Immunol; 1998 Apr; 160(7):3101-10. PubMed ID: 9531264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BALB/c invariant chain mutant mice display relatively efficient maturation of CD4+ T cells in the periphery and secondary proliferative responses elicited upon peptide challenge.
    Kenty G; Bikoff EK
    J Immunol; 1999 Jul; 163(1):232-41. PubMed ID: 10384121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
    Singh N; Van Kaer L
    J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
    Bertolino P; Rabourdin-Combe C
    Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice.
    Bikoff EK; Wutz G; Kenty GA; Koonce CH; Robertson EJ
    J Immunol; 2001 Apr; 166(8):5087-98. PubMed ID: 11290790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
    Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
    J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
    Honey K; Forbush K; Jensen PE; Rudensky AY
    J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DM-mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules.
    Stebbins CC; Peterson ME; Suh WM; Sant AJ
    J Immunol; 1996 Dec; 157(11):4892-8. PubMed ID: 8943393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
    Felix NJ; de Serres S; Meyer AA; Ting JP
    J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class II expression in double mutant mice lacking invariant chain and DM functions.
    Kenty G; Martin WD; Van Kaer L; Bikoff EK
    J Immunol; 1998 Jan; 160(2):606-14. PubMed ID: 9551894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
    Fineschi B; Sakaguchi K; Appella E; Miller J
    J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DM and DO shape the repertoire of peptide-MHC-class-II complexes.
    Karlsson L
    Curr Opin Immunol; 2005 Feb; 17(1):65-70. PubMed ID: 15653313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.
    Mukherjee R; Chaturvedi P; Lee-Chan E; Singh B
    Mol Immunol; 2008 Apr; 45(8):2166-76. PubMed ID: 18279957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo functions mediated by the p41 isoform of the MHC class II-associated invariant chain.
    Takaesu NT; Lower JA; Yelon D; Robertson EJ; Bikoff EK
    J Immunol; 1997 Jan; 158(1):187-99. PubMed ID: 8977190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.